Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Screening for carcinoma in situ in the contralateral testicle in patients with testicular cancer: a population-based study (DaTeCa 03 study)

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Human endogenous retroviruses and their implication for immunotherapeutics of cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Safety and dose modification for patients receiving niraparib

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Characterisation and localisation of the endocannabinoid system components in the adult human testis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. High-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Screening programmes for contralateral carcinoma in situ (CIS) testis in patients with unilateral germ-cell cancer (GCC) have never been evaluated. We investigated the effect of screening for contralateral CIS in a large nation-wide, population-based study.

PATIENTS AND METHODS: A contralateral single-site biopsy was offered to 4130 patients in whom GCC had been diagnosed in 1984-2007 (screened cohort); 462 patients in whom GCC was diagnosed in 1984-1988 comprised the unscreened cohort. Cases with CIS were offered radiotherapy. Initially CIS-negative biopsies in patients with metachronous GCC were revised according to today's standards. Risk for metachronous GCC was estimated using cumulative incidence and the Cox proportional hazards model.

RESULTS: In the screened cohort, contralateral CIS was found in 181 (4.4%) patients. The cumulative incidence of metachronous GCC after 20 years was 1.9% in the screened cohort and 3.1% in the unscreened cohort (P = 0.097), hazard ratio (HR) for the unscreened cohort: 1.59 (P = 0.144). Expert revision with contemporary methodology of CIS-negative biopsy samples from patients with metachronous cancer revealed CIS in 17/45 (38%) cases. Decreased risks for metachronous GCC were related to older age at diagnosis (HR 0.52 per 10 years, P < 0.001) and chemotherapy (HR 0.35, P = 0.002). Limitations include the small number of patients in the unscreened cohort and the retrospective study design.

CONCLUSIONS: Our evaluation of a national population-based screening programme for contralateral CIS in patients with testicular cancer showed no significant difference in the risk for metachronous GCC between a screened and an unscreened cohort. Single-site biopsy including modern immunohistochemistry does not identify all cases of CIS.

Original languageEnglish
JournalAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume26
Issue number4
Pages (from-to)737-42
ISSN0923-7534
DOIs
Publication statusPublished - 2015

ID: 44837142